Squarepoint’s ALX Oncology ALXO Stock Holding History

Squarepoint’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97K	Buy	+46,869	New	+$83.9K	﹤0.01%	4209
2025 Q3	–	Sell	-58,307	Closed	-$24.2K	–	4328
2025 Q2	$24.2K	Buy	+58,307	New	+$29.4K	﹤0.01%	4378
2024 Q4	–	Sell	-137,983	Closed	-$251K	–	4991
2024 Q3	$251K	Buy	+137,983	New	+$513K	﹤0.01%	3561
2024 Q2	–	Sell	-106,356	Closed	-$1.19M	–	4013
2024 Q1	$1.19M	Buy	+106,356	New	+$1.49M	﹤0.01%	2471
2023 Q2	–	Sell	-63,231	Closed	-$286K	–	3527
2023 Q1	$286K	Buy	+63,231	New	+$479K	﹤0.01%	2601
2022 Q4	–	Sell	-13,615	Closed	-$130K	–	3145
2022 Q3	$130K	Buy	+13,615	New	+$159K	﹤0.01%	2763
2022 Q2	–	Sell	-13,189	Closed	-$223K	–	2847
2022 Q1	$223K	Sell	13,189 -34,016	-72%	-$581K	﹤0.01%	2429
2021 Q4	$1.01M	Buy	+47,205	New	+$2.04M	﹤0.01%	1680

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Squarepoint's ALXO Position: Q2 2026 in Review

Squarepoint opened a new position in ALX Oncology (ALXO) in Q2 2026: 46,869 shares worth $97K. The stake represents ﹤0.01% of the portfolio and ranks #4209 among its holdings. This is a return to the name: Squarepoint previously reported a position in ALXO as recently as Q2 2025.

Squarepoint first reported a position in ALXO in Q4 2021 and has held it in 8 quarters since. The position peaked at $1.19M in Q1 2024. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

Squarepoint held 46,869 shares of ALX Oncology worth $97K as of Q2 2026.
ALX Oncology was a new Squarepoint position in Q2 2026.
ALX Oncology made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4209 holding.
Squarepoint first reported a position in ALX Oncology in Q4 2021 and has held it in 8 quarters since.
Squarepoint's ALX Oncology position peaked at $1.19M in Q1 2024.
94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.